NEWS

• • • Diadem awarded US patent for AlzoSure® Alzheimer’s disease prediction technology
      Milan, FL and Milan, Italy – October 19, 2026
      Diadem has been awarded a US patent extending protection for its AlzoSure® biomarker technology. The patent covers methods for detecting and measuring U-p53AZ, a protein variant associated with Alzheimer’s disease, ahead of the planned commercial launch of AlzoSure® Predict, a blood test designed to assess the risk of progression to Alzheimer’s disease.
• • • Seed Healthcare Leads Strategic Investment in Diadem
      Milan, FL and Milan, Italy – August 13, 2026
      Seed Healthcare today announced it has led a strategic investment in Diadem, an Italian company developing blood-based diagnostics for the early detection of Alzheimer’s disease and other neurodegenerative conditions.

• • • Diadem Unveils Novel Findings on Early Alzheimer’s Disease Detection Using p53-Specific Antibody at CTAD 2024
      Milano, Italy – November 1, 2024
      Diadem SpA, in partnership with researchers from the University of Texas Medical Branch, led by Prof. Rakez Kayed from the Mitchell Center for Neurodegenerative ….

• Diadem appoints Michael Rasche as Chief Executive Officer
  Milan, Italy – July 10 2024
  Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer’s disease (AD)

• Diadem Announces Publication of Clinical Study Confirming Its AlzoSure® Predict Blood Test Can Accurately Predict Progression to Alzheimer’s Disease Six Years Before Diagnosis
  Milan, ITALY – May 16, 2022
  Diadem SpA today announced publication of the results of a clinical validation study of its AlzoSure® Predict prognostic blood test for Alzheimer’s disease (AD) ….

• Diadem Announces Publication of Peer-Reviewed Article Describing How Post-Translational Modifications of p53 Variants May Contribute to Development of Alzheimer’s Disease
  Milan, ITALY – April 28, 2022
  Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced …

• Diadem Announces First Closing of €10 Million Equity Financing for Its AlzoSure® Predict Prognostic Blood Test for Alzheimer’s Disease
  Milan, Italy, March 28, 2022
  Diadem SpA, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced the closing of the first tranche ….

• Diadem Presents Data at AD/PD™ 2022 International Conference Demonstrating Its New AlzoSure® Confirm Blood Test Has the Potential to Accurately Diagnose Alzheimer’s Disease
  Milan, ITALY and Barcelona, SPAIN – March 22, 2022
  Diadem srl, a company developing blood-based tests for the early prediction and diagnosis of Alzheimer’s disease (AD), today announced that …

• European Investment Bank to Provide a €7.5 Million Loan to Support Further Research and Development of Diadem’s AlzoSure® Predict Blood Test for Alzheimer’s Disease
  Luxembourg City (Luxembourg) and Brescia (Italy) – March 07, 2022
  The European Investment Bank (EIB) has awarded a €7.5 million loan to Diadem Srl, a company developing the first blood-based prognostic test for the early prediction of Alzheimer’s disease …

• Diadem Receives CE-IVD Certification to Market Its AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer’s Disease in Europe
  Brescia, Italy – February 28, 2022
  Diadem Srl today announced CE IVD certification for its AlzoSure® Predict prognostic blood test for the early prediction of Alzheimer’s disease …

• FDA Grants Breakthrough Device Designation to Diadem’s AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer’s Disease
  San Francisco, CA – January 18, 2022
  Diadem U.S., Inc.,(a subsidiary of Diadem Srl) a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced …

• Presentation at Clinical Trials on Alzheimer’s Disease Meeting Highlights How Diadem’s AlzoSure® Predict Can Enable AD Clinical Trials and Screening for Early Detection of AD
  Milan, ITALY and Boston, MA, USA – November 15, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today reported that it presented …

• Diadem Presents Data at 22nd International Conference on Alzheimer’s Drug Discovery Highlighting Its Blood-Based Biomarker Test Is 84% Concordant with Amyloid Brain Imaging
  Milan, ITALY – October 6, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease, today announced release …

• Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer’s Disease
  Milan, ITALY – September 23, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced release …

• Diadem Announces Publication of Clinical Data Showing Its AlzoSure® Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease Six Years Before Diagnosis
  Milan, ITALY – August 26, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced results …

• Diadem Awarded Patent in China for Its AlzoSure® Prognostic Biomarker Technology that Accurately Predicts Progression to Alzheimer’s Disease
  Milan, ITALY – August 4, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced that its AlzoSure® prognostic…

• Diadem Presents Clinical Validation Interim Data Confirming Its AlzoSure® Prognostic Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease
  Milan, ITALY – May 18, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today …

• Diadem Presents New Data at AAIC® Symposium Showing Its Blood-Based Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease 7 Years Before Symptoms Occur
  Milan, ITALY – May 13, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today …

• New Scientific Publications Show Diadem’s Blood-Based AlzoSure® Biomarker Test Can Predict Which Patients Will Progress to Alzheimer’s Disease Years Before Symptoms Occur
  Milan, ITALY – February 01, 2021
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced the publication…

• Diadem Presents Clinical Data and Commercialization Plans for Its AlzoSure® Prognostic Biomarker Test at 2020 Alzheimer’s Disease International Conference
  Milan, ITALY – December 11, 2020
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today reported that it hosted a Symposium on its prognostic biomarker…

• Diadem Names Dr. Tamas Bartfai Chair of Its Medical Advisory Board
  Milan, ITALY – December 1, 2020
  Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced that noted neuroscientist and Alzheimer’s disease…

• Development of Blood-Based Alzheimer’s Prognostic Propels Diadem to Finalist Status for Both the Gaetano Marzotto Company Prize and 2030 Social Impact Special Prize
  Milan, ITALY – November 16, 2020
  pool of 600 applicants. The companies were analyzed by experts representing relevant public, private, financial, technological and specialist…

• Diadem Names Clinical Diagnostics Industry Veteran Paul Kinnon as CEO
  Milan, ITALY – October 19, 2020
  Diadem srl, a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, today announced that Paul Kinnon has been named…